AAV Vector Encoding FXN for Friedreich’s Ataxia

Assignee: Cornell University & collaborators (licensed to Lexeo Therapeutics, Inc.)
Example Patent: US 9,066,966 B2 (Representative patent in the licensed family)
Filing / Priority: Before 2012 (priority dates back to foundational frataxin gene therapy work)
Issued: 2015–2016 (example patent grant date for US 9,066,966 B2)
Expiration: ~2033 (subject to adjustment and maintenance)

What This Patent Covers

This patent family broadly protects adeno‑associated viral (AAV) vectors encoding the FXN gene — the gene product deficient in Friedreich’s ataxia — and methodologies for treating cardiac and other manifestations of this genetic disease by administering the vector to deliver functional frataxin to affected tissues.

Core elements include:

AAV vector constructs comprising a nucleotide sequence encoding the human frataxin (FXN) protein, designed to be delivered into cells.
Methods of treatment involving administering the AAV‑FXN vector to subjects in need, particularly to prevent or reverse cardiomyopathy by restoring frataxin expression in cardiac muscle and mitochondria.
Compositions and dosing strategies tailored for efficient gene delivery and therapeutic effect in models of Friedreich’s ataxia cardiomyopathy.

This class of patents forms the composition‑of‑matter and method‑of‑use backbone for Lexeo’s lead gene therapy candidate LX2006, which has shown clinically meaningful improvements in cardiac biomarkers and function in Phase 1/2 trials, and received FDA Breakthrough Therapy designation a regulatory milestone highlighting its potential impact.

Why This Patent Is Important

Directly tied to Lexeo’s lead asset: LX2006 is the company’s most advanced clinical program and the one most likely to generate future revenue if it advances to approval and commercialization.
Provides core exclusivity: The AAV‑FXN vector patent gives Lexeo freedom to operate and market protection for its gene therapy approach, helping guard against competitors infringing the same mechanism.
Supports valuation & partnerships: Patents with composition‑of‑matter and therapeutic method claims are among the highest commercial value categories of IP in gene therapy, enhancing Lexeo’s strategic position for financing and collaboration.
Large unmet medical need: Friedreich’s ataxia cardiomyopathy has no approved disease‑modifying treatments, making patent protection for a first‑in‑class therapy highly valuable in both health impact and economic terms.

Note: Because Lexeo relies on in‑licensed patents and pending applications (many jointly owned with research institutions such as Cornell), its portfolio includes multiple composition and method applications that have not yet issued but are expected to form additional long‑term protection for LX2006 (potentially extending into the early 2040s).

BioTech IP Review